1,726 results match your criteria Annals of hepatology[Journal]


MH Newsletter.

Authors:

Ann Hepatol 2020 Jul - Aug;19(4):448

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324101PMC

Identification of mutations in the S gene of Hepatitis B Virus in HIV positive Mexican patients with occult Hepatitis B virus infection.

Ann Hepatol 2020 Jun 24. Epub 2020 Jun 24.

Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. Electronic address:

Introduction And Aim: Occult hepatitis B virus infection (OBI) is characterized by the presence of replication-competent hepatitis B virus (HBV) DNA in the liver and/or serum of patients with undetectable levels of the HBV surface antigen (HBsAg). Due to the shared infection routes HIV positive patients are at higher risk of developing OBI, thus, the aim of this study was to determine the frequency of OBI in Mexican HIV-infected patients and to identify mutations in the HBV S gene that could be associated to the development of OBI.

Materials And Methods: Plasma samples from 50 HIV-infected patients with undetectable levels of the HBsAg were obtained and analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.06.002DOI Listing

Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease.

Ann Hepatol 2020 Jun 15. Epub 2020 Jun 15.

Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China. Electronic address:

Introduction And Objectives: Autophagy has emerged as a critical regulatory pathway in non-alcoholic fatty liver disease (NAFLD). However, the variability of hepatic autophagy during NAFLD development remains controversial. This study aimed to elucidate the dynamics of hepatic autophagy and its underlying mechanism during NAFLD development both in vivo and in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.06.001DOI Listing

Performing thermal ablations for hepatomas - is it a worthy skill for hepatologists?

Ann Hepatol 2020 May 29. Epub 2020 May 29.

Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Introduction And Objectives: The role of hepatologists in the management of hepatocellular carcinoma (HCC) is not well defined. We conducted a cross-sectional study to assess the feasibility of hepatology-directed HCC treatment.

Patients: We evaluated 107 patients with newly diagnosed HCC, undergoing locoregional therapy as the first therapy between January 2017 and February 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.05.004DOI Listing

LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2.

Ann Hepatol 2020 May 26. Epub 2020 May 26.

The Interventional Medicine Center the Affiliated Hospital of Qingdao University China, Qingdao 266003, Shandong Province, China. Electronic address:

Introduction And Objectives: Hepatocellular carcinoma (HCC) is the second most lethal cancer around the world, with poor survival rate and high metastasis rate in patients. Long noncoding RNAs (lncRNAs) have been reported to modulate the initiation and development of liver cancer. We aimed to investigate the role of lncRNA MAGI2-AS3 in HCC and underlying mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.007DOI Listing

Weekend admissions with ascites are associated with delayed paracentesis: A nationwide analysis of the 'weekend effect'.

Ann Hepatol 2020 Jun 4. Epub 2020 Jun 4.

Department of Gastroenterology, UMMS-Baystate Medical Center, Springfield, MA, USA.

Introduction And Objectives: Weekend admissions has previously been associated with worse outcomes in conditions requiring specialists. Our study aimed to determine in-hospital outcomes in patients with ascites admitted over the weekends versus weekdays. Time to paracentesis from admission was studied as current guidelines recommend paracentesis within 24h for all patients admitted with worsening ascites or signs and symptoms of sepsis/hepatic encephalopathy (HE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.05.005DOI Listing

Inhibition of fatty acid synthase (FASN) affects the proliferation and apoptosis of HepG2 hepatoma carcinoma cells via the β-catenin/C-myc signaling pathway.

Ann Hepatol 2020 Jul - Aug;19(4):411-416. Epub 2020 Mar 31.

Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China. Electronic address:

Introduction And Objectives: Research in the last few years has proven that inhibition of fatty acid synthase (FASN) suppresses the migration and invasion of hepatoma carcinoma cells. This study aims to explore the effect of fatty acid synthase knockdown on the apoptosis and proliferation of HepG2 cells.

Materials And Methods: The human liver cancer cell line HepG2 was cultured and then transfected with FASN-specific siRNA and negative control RNAi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.03.005DOI Listing

Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease.

Ann Hepatol 2020 Jun 6. Epub 2020 Jun 6.

Traslational Research Unit, Medica Sur Clinic & Foundation, Puente de Piedra 150, Toriello Guerra, Tlalpan, Z.C. 14050 Mexico City, Mexico. Electronic address:

The obesity pandemic that affects the global population generates one of the most unfavorable microenvironmental conditions in the hepatocyte, which triggers the metabolic hepatopathy known as non-alcoholic fatty liver; its annual rates increase in its prevalence and does not seem to improve in the future. The international consortia, LITMUS by the European Union and NIMBLE by the United States of America, have started a race for the development of hepatic steatosis and steatohepatitis reliable biomarkers to have an adequate diagnosis. MicroRNAs have been proposed as diagnostic and prognostic biomarkers involved in adaptation to changes in the liver microenvironment, which could improve clinical intervention strategies in patients with hepatic steatosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.012DOI Listing
June 2020
2.193 Impact Factor

Granulocyte colony stimulating factor: A potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis.

Ann Hepatol 2020 Jun 6. Epub 2020 Jun 6.

Division of Gastroenterology, University of British Columbia and Vancouver General Hospital, Canada. Electronic address:

Liver cirrhosis accounts for over 2 million deaths annually worldwide. A subset of these patients - those with alcoholic hepatitis and decompensated cirrhosis, have abysmal short-term survival. Liver transplant is the only intervention of proven survival benefit; however organ availability is a major limitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.011DOI Listing

Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis.

Ann Hepatol 2020 Jun 6. Epub 2020 Jun 6.

Federal University of Health Sciences of Porto Alegre, Graduate Program in Medicine: Hepatology, Brazil; Irmandade Santa Casa de Misericórdia de Porto Alegre, Brazil. Electronic address:

Infections are a frequent complication and a major cause of death among patients with cirrhosis. The important impact of infections in general and especially spontaneous bacterial peritonitis on the course of disease and prognosis of patients with cirrhosis has been recognized for many years. Nevertheless, such importance has recently increased due to the comprehension of infection as one of the most prominent risk factors for patients to develop acute-on-chronic liver failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.010DOI Listing

Propranolol for infantile hepatic hemangioendothelioma: Clinical evaluation of drug efficacy and safety using a single-center patient cohort.

Ann Hepatol 2020 May 26. Epub 2020 May 26.

Department of General Surgery, Shanghai Children's Medical Center (National Children's Medical Center-Shanghai), Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address:

Introduction And Objectives: Infantile hepatic hemangioendothelioma (IHHE) is a benign liver tumor, associated with hypothyroidism and vascular malformations along the skin, brain, digestive tract and other organs. Here, we determined a single-center patient cohort by evaluating the effectiveness and safety of propranolol and sirolimus for the treatment of IHHE.

Patients And Methods: We performed a monocentric and observational study, based on clinical data obtained from 20 cases of IHHE treated with oral propranolol and sirolimus at the Shanghai Children's Medical Center (SCMC), between December 2017 and April 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.008DOI Listing
May 2020
2.193 Impact Factor

Maternal knowledge of the risk of vertical transmission and offspring acquisition of hepatitis B.

Ann Hepatol 2020 Jul - Aug;19(4):388-395. Epub 2020 May 20.

University of Minnesota Masonic Children's Hospital, Minneapolis, MN, United States.

Introduction And Objectives: Universal vaccination at birth and in infancy is key to the elimination of chronic hepatitis B infection. We aimed to assess hepatitis B immune-prophylaxis and perinatal transmission knowledge, in a large and ethnically diverse cohort of previously pregnant North American women, chronically infected with hepatitis B.

Materials And Methods: The Hepatitis B Research Network (HBRN) is comprised of 28 Clinical Centers in the United States and Canada. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.006DOI Listing

Prevalence of NAFLD in Guatemala following exposure to a protein-energy nutrition intervention in early life.

Ann Hepatol 2020 Jul - Aug;19(4):373-379. Epub 2020 May 16.

Department of Pediatrics, Emory School of Medicine, Atlanta, GA, United States.

Introduction And Objectives: The global prevalence of non-alcoholic fatty liver disease (NAFLD) is approximately 25%, with Hispanic populations at greatest risk. We describe the prevalence of NAFLD in a cohort of Guatemalan adults and examine whether exposure to a protein-energy supplement from conception to two years is associated with lower prevalence of NAFLD.

Materials And Methods: From 1969 to 1977, four villages in Guatemala were cluster-randomized to receive a protein-energy supplement (Atole) or a no-protein, low-energy beverage (Fresco). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.004DOI Listing

Telemedicine, COVID-19 and liver diseases: Revamping remote care initiatives in hepatology.

Authors:
Marco Arrese

Ann Hepatol 2020 Jul - Aug;19(4):339-340. Epub 2020 May 23.

Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.05.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244434PMC

The imperative for an updated cirrhosis surgical risk score.

Ann Hepatol 2020 Jul - Aug;19(4):341-343. Epub 2020 May 15.

Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, United States; Leonard David Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States. Electronic address:

The burden of cirrhosis is increasing, as is the need for surgeries in patients with cirrhosis. These patients have increased surgical risk relative to non-cirrhotic patients. Unfortunately, currently available cirrhosis surgical risk prediction tools are non-specific, poorly calibrated, limited in scope, and/or outdated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.005DOI Listing

Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?

Ann Hepatol 2020 Jul - Aug;19(4):380-387. Epub 2020 May 12.

Italian Liver Foundation, Basovizza, Trieste, Italy. Electronic address:

Introduction And Objectives: Surrogate biomarkers of liver fibrosis developed in tertiary care are increasingly used in general populations. We evaluated the association between liver stiffness (LS) and five continuous (AST/ALT, APRI, Forns Index, FIB-4, GGT) and two discrete biomarkers (BARD, BAAT) in a general population.

Patients And Methods: 636 (29%) of the 2159 citizens of the Bagnacavallo Study had LS measured by transient elastography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.003DOI Listing
May 2020
2.193 Impact Factor

Liquid biopsy in chronic liver disease.

Ann Hepatol 2020 May 6. Epub 2020 May 6.

Innbiogem SC at National Laboratory for Services of Research, Development, and Innovation for the Pharma and Biotech Industries (LANSEDI) of CONACyT Vitaxentrum group, Monterrey, N.L., Mexico; National Institute of Pediatrics, Mexico City, Mexico.

Chronic liver diseases account for a considerable toll of incapacities, suffering, deaths, and resources of the nation's health systems. They can be prevented, treated or even cured when the diagnosis is made on time. Traditional liver biopsy remains the gold standard to diagnose liver diseases, but it has several limitations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.03.008DOI Listing

Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients.

Ann Hepatol 2020 Jul - Aug;19(4):367-372. Epub 2020 May 11.

Department of Hepatology, Endowed Department of Liver Cirrhosis Therapeutics, Japan; Department of Premier Preventive Medicine, Japan.

Introduction And Objectives: We examined whether Mac-2-binding protein glycosylation isomer (M2BPGi) levels could be a predictive marker for the presence of esophagogastric varices (EGV) in cirrhotic patients after hepatitis C virus (HCV) eradication with direct-acting antivirals (DAAs).

Patients And Methods: A total of 102 cirrhotic patients with HCV infection treated with DAAs were enrolled. Esophagogastroduodenoscopy was performed in 84 of the patients before treatment (Cohort A), in 66 after treatment (Cohort B), and in 48 at both time points (Cohort C). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.002DOI Listing

The liver in times of COVID-19: What hepatologists should know.

Ann Hepatol 2020 Jul - Aug;19(4):353-358. Epub 2020 May 18.

Latin American Liver Research, Educational and Awareness Network (LALREAN) Pilar, Provincia de Buenos Aires Argentina, Argentina; Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Chile. Electronic address:

The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding how the infection affects the liver and relevance of pre-existing liver disease as a risk factor for acquiring the infection or having a severe disease are still scarce. Also, considerations in liver transplant patients, those having hepatocellular carcinoma or under immunosuppressive therapy are being matter of analysis as information is being generated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233236PMC
May 2020
2.193 Impact Factor

A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management.

Ann Hepatol 2020 Jul - Aug;19(4):396-403. Epub 2020 Apr 23.

Gastroenterology Department, Hospital de la Samaritana, Bogotá, Colombia.

Introduction & Objectives: Liver cirrhosis is a major cause of mortality worldwide. Adequate diagnosis and treatment of decompensating events requires of both medical skills and updated technical resources. The objectives of this study were to search the demographic profile of hospitalized cirrhotic patients in a group of Latin American hospitals and the availability of expertise/facilities for the diagnosis and therapy of decompensation episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.03.007DOI Listing

Blood lead level is associated with advanced liver fibrosis in patients with non-alcoholic fatty liver disease: A nationwide survey (NHANES 2011-2016).

Ann Hepatol 2020 Jul - Aug;19(4):404-410. Epub 2020 Apr 4.

Center for Liver Diseases and Masses, Rutgers Robert Wood Johnson School of Medicine, 1 Robert Wood Johnson Place, New Brunswick, New Brunswick, NJ, United States.

Introduction And Objectives: Non-Alcoholic Fatty Liver Disease (NAFLD) is linked to obesity and metabolic syndrome, but increasing evidence also implicates environmental toxins. In this study, we aim to show that in elevated blood Lead levels in NAFLD patients result in worsening liver fibrosis.

Materials And Methods: 30,172 patients from NHANES 2011-2016 met inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.03.006DOI Listing

Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease.

Ann Hepatol 2020 May - Jun;19(3):227-229

Liver Research Unit, Medica Sur Clinical Foundation, Mexico City, Mexico; Faculty of Medicine. National Autonomous University of Mexico, Mexico City, Mexico. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.04.001DOI Listing
April 2020
2.193 Impact Factor

Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.

Ann Hepatol 2020 Jul - Aug;19(4):359-366. Epub 2020 Mar 21.

Section of Endocrinology, Diabetes and Metabolism, University of Verona, Verona, Italy.

The prevalence of nonalcoholic fatty liver disease (NAFLD) is continuing to rise in many countries, paralleling the epidemic of obesity worldwide. In the last years, the concept of metabolically healthy obesity [MHO, generally defined as obesity without metabolic syndrome (MetS)] has raised considerable scientific interest. MHO is a complex phenotype with risks intermediate between metabolically healthy individuals with normal-weight (NWMH) and patients who are obese and metabolically unhealthy (MUO, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.03.001DOI Listing

miRNA-338-3p/CAMK IIα signaling pathway prevents acetaminophen-induced acute liver inflammation in vivo.

Ann Hepatol 2020 Mar 20. Epub 2020 Mar 20.

Department of Infectious Diseases, The Hospital of Yan 'an People, Shaanxi 716000, China. Electronic address:

Introduction And Objectives: N-acetyl-p-aminophenol (APAP)-induced liver injury is a major clinical challenge worldwide. The present study investigated the molecular role of microRNA (miR)-338-3p in the development of APAP-induced acute liver injury.

Materials And Methods: B6 mice were treated with an miR-338-3p agomir, antagomir, and intraperitoneally injected with APAP 24h later to induce acute liver injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.03.003DOI Listing
March 2020
2.193 Impact Factor

Bacterial infections in cirrhosis: Current treatment.

Ann Hepatol 2020 May - Jun;19(3):238-244. Epub 2019 Nov 21.

Hepatology and Liver Transplantation Unit, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico. Electronic address:

Bacterial infections frequently cause decompensating events in cirrhotic patients and are also the most common factor identified for the development of acute-on-chronic liver failure (ACLF). The increase in the prevalence of infections caused by multidrug-resistant (MDR) microorganisms has resulted in the reduced effectiveness of empiric antimicrobial treatment. We conducted a PubMed search from the last 20 years using the Keywords cirrhosis; multidrug-resistant; infections; diagnosis; treatment; prophylaxis; monitoring; sepsis; nutrition and antibiotic resistant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.09.011DOI Listing
November 2019

The impact of different infectious complications on mortality of hospitalized patients with liver cirrhosis.

Ann Hepatol 2020 Jul - Aug;19(4):427-436. Epub 2020 Mar 6.

Department of Gastroenterology, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Vasco de Quiroga 15, Mexico City, Mexico. Electronic address:

Introduction And Objectives: Bacterial infections are common complications in patients with cirrhosis and are associated with poor prognosis. There are no studies that analyze the impact of different infectious complications in the mortality of these patients, so we aimed to perform this evaluation.

Materials And Methods: We performed a case-control study in adult patients with cirrhosis with a follow-up period of one year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.02.005DOI Listing

Platelets level variability during the first year after liver transplantation in the risk prediction model for recipients mortality.

Ann Hepatol 2020 Jul - Aug;19(4):417-421. Epub 2020 Mar 21.

Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, 59 Nowogrodzka St, Warsaw, Poland. Electronic address:

Introduction And Objectives: Many scoring systems in liver diseases use static values of liver function parameters. These parameters may change significantly in liver transplant (LTx) recipients over time due to various processes. The study was aimed at building a new model for survival prediction after LTx based on variability of selected parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.03.004DOI Listing

Viral eradication restores normal iron status in chronic hepatitis C patients with abnormal iron studies.

Ann Hepatol 2020 Jul - Aug;19(4):422-426. Epub 2020 Mar 17.

Department of Internal Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, United States; Iowa City Veterans Administration Medical Center, Iowa City, IA, United States; Free Radical and Radiation Biology Program, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, United States. Electronic address:

Introduction And Objectives: Abnormal serum iron studies are seen in a third or more of patients with chronic hepatitis C infection (HCV), where they have been linked to accelerated fibrosis progression and increased risk of hepatocellular carcinoma and sometimes lead to concern for coexisting hereditary hemochromatosis. The aim of this study was to assess the effect of HCV eradication in patients with abnormal serum iron studies prior to treatment with direct-acting antiviral agents (DAAs).

Patients: HCV-infected subjects with iron studies obtained before and after successful treatment with DAAs were identified (n=27). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.03.002DOI Listing

New model predicting gastroesophageal varices and variceal hemorrhage in patients with chronic liver disease.

Ann Hepatol 2020 May - Jun;19(3):287-294. Epub 2020 Feb 11.

Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Electronic address:

Introduction And Objectives: The predictors for gastroesophageal varices (GOV) and hemorrhage development have not been well studied in different liver diseases or different population. This study aimed to evaluate whether a new algorithm focusing on chronic hepatitis B (CHB) patients is also applicable to other chronic liver diseases (CLDs) in Chinese population.

Patients Or Materials And Methods: We retrospectively analyzed 659 CHB patients and 386 patients with other CLDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.12.007DOI Listing
February 2020

Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America.

Ann Hepatol 2020 Jul - Aug;19(4):437-445. Epub 2020 Feb 8.

Division of Gastroenterology, Toronto General Hospital, University Health Network, Toronto, Canada. Electronic address:

Introduction And Objectives: The prevalence of alcohol, tobacco, and coffee use and association with liver health among North Americans with Chronic Hepatitis B (CHB) infection has not been well described.

Materials And Methods: The Hepatitis B Research Network includes an observational study of untreated CHB adults enrolled at 21 sites in the United States and Canada. Alcohol use was categorized as none, moderate, and at-risk based on the definition from the National Institute on Alcohol Abuse and Alcoholism; tobacco use as never, current and former; coffee use as none, 1-2 cups/day, and ≥3 cups/day. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.01.005DOI Listing
February 2020

Expanding TACTICS trial into a different setting in hepatocellular carcinoma.

Ann Hepatol 2020 May - Jun;19(3):230-231. Epub 2020 Feb 19.

Sao Paulo Clínicas Liver Cancer Group - Hospital das Clínicas Complex, Instituto do Cancer do Estado de São Paulo, University of São Paulo School of Medicine, Brazil.

Systemic treatment for hepatocellular carcinoma (HCC) is recommended for patients with advanced stage and for those who progressed on locoregional modalities. The first agent approved for advanced HCC was sorafenib, and it remains one of the cornerstones of systemic treatment. In the past years, immunotherapy has shown promising results and has been incorporated into the treatment armamentarium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.02.001DOI Listing
February 2020

How far is Mexico from Viral Hepatitis Global Health Sector Strategy 2030 targets.

Ann Hepatol 2020 Mar - Apr;19(2):123-125

Department of Molecular Biology in Medicine, Civil Hospital of, Guadalajara "Fray Antonio Alcalde" and Health Sciences Center, University of Guadalajara. Guadalajara, Jalisco, Mexico.

In 2016 WHO member states endorsed the 69 World Health Assembly's Global Health Sector Strategies (GHSS) towards eliminating Hepatitis B (HBV) infections by 2030. Substantial progress has been made in Mexico regarding HBV vaccination, blood safety and health-care setting injection safety but minor progress has been identified regarding timely HBV birth-dose coverage, access to diagnostic testing and treatment. Most importantly, Mexico's lack of a national plan for the fight against viral hepatitis was identified as a major obstacle for the development and implementation of actions and procuring funding Insight of these deficiencies, we propose six actions that are in line with GHSS strategic directions to better allow Mexico to reach the goal of eliminating viral hepatitis by 2030. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.02.003DOI Listing
February 2020

Antiretroviral Therapies for Human Immunodeficiency Virus and Liver Disease: Challenges and opportunities.

Ann Hepatol 2020 Mar - Apr;19(2):121-122

Department of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico. Electronic address:

The post antiretroviral therapy (ART) era for human immunodeficiency virus (HIV) infection resulted in a dramatically increased proportion of deaths attributed to liver-related causes in patients with HIV treated with ART. Additionally, as patients become older as a result of effective ART, liver-related conditions and application of safe therapies are now major concerns in the setting of HIV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.02.004DOI Listing
February 2020

Where is the focus on hepatitis C research after the introduction of DAAs: To Understand, knowledge, prevent or cure hepatitis C?

Ann Hepatol 2020 Mar - Apr;19(2):119-120

Biochemistry and Molecular Medicine Department, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, NL, México.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.02.002DOI Listing
February 2020

Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population.

Ann Hepatol 2020 May - Jun;19(3):251-257. Epub 2020 Feb 5.

Translational Research Unit, Medica Sur Clinical Foundation, Mexico City, Mexico. Electronic address:

Introduction And Objectives: Polycystic ovary syndrome (PCOS) is the most common endocrinology disorder in women of reproductive age; these patients have a higher risk of suffering from non-alcoholic fatty liver disease (NAFLD). We determine the frequency of NAFLD in Mexican patients with PCOS and matched-controls.

Patients And Methods: Cross-sectional study, with 98 women of 18-44 years old. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.01.004DOI Listing
February 2020
2.193 Impact Factor

A fat containing combined neuroendocrine carcinoma and hepatocellular carcinoma in the liver: A case report.

Ann Hepatol 2020 Feb 13. Epub 2020 Feb 13.

Department of Gastroenterology and Hepatology, Kyoto Katsura Hospital, Kyoto, Japan.

A 79-year-old man was admitted to our hospital because of increased hepatobiliary enzyme levels. Dynamic computed tomography and magnetic resonance imaging showed a liver tumor measuring 60mm containing fat foci at the cranial aspect of the tumor. We diagnosed the patient with hypovascular hepatocellular carcinoma (HCC) and fat deposition, and performed a caudate lobe resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.01.006DOI Listing
February 2020

Circ-PRMT5 enhances the proliferation, migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis.

Ann Hepatol 2020 May - Jun;19(3):269-279. Epub 2020 Jan 27.

Department of General surgery, Xiangyang NO. 1 People's Hospital, Affiliated Hospital of Hubei University of Medicine, Xiangyang, Hubbei, China.

Introduction And Objectives: Circular RNA (circRNA) has been demonstrated as a critical regulator in human cancer, including hepatocellular carcinoma (HCC). Nevertheless, the role of circ-PRMT5 in HCC remains largely unknown.

Patients Or Materials And Methods: The real-time quantitative polymerase chain reaction (RT-qPCR) was performed to assess the expression levels of circ-PRMT5, miR-188-5p and anti-Hexokinase II (HK2) in HCC tissues and cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.01.002DOI Listing
January 2020

Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?

Ann Hepatol 2020 May - Jun;19(3):258-264. Epub 2020 Feb 1.

Gastroenterology Service, Internal Medicine Department, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, N.L., Mexico.

Introduction: Cirrhosis and liver cancer are currently common causes of death worldwide. The global epidemic of obesity has increased the incidence of nonalcoholic fatty liver disease (NAFLD) and cirrhosis in recent years. Advanced fibrosis increases the morbimortality rate in NAFLD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.01.003DOI Listing
February 2020
2.193 Impact Factor

Chemotherapy-associated steatohepatitis.

Ann Hepatol 2020 Jan 30. Epub 2020 Jan 30.

Service d'Hépato-gastroentérologie et Transplantation, France; INSERM 1183, France.

Some drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase. The hepatotoxic phenotype developed from treatment with such drugs is known as "CASH" for "Chemotherapy-induced Acute Steatohepatitis". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.11.012DOI Listing
January 2020

Role of CD98 in liver disease.

Ann Hepatol 2020 Jan 30. Epub 2020 Jan 30.

Department of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, 145 Piedmont Ave SE, Atlanta, GA, USA; Department of Biology, Center for Diagnostics and Therapeutics, Georgia State University, 145 Piedmont Ave SE, Atlanta, GA, USA. Electronic address:

CD98 is a multifunctional glycoprotein that is involved in various biological processes such as amino acid transport, cell adhesion, diffusion, adhesion, and proliferation. The role of CD98 in liver disease has not thoroughly been examined and is limited reports in the literature. Among these reports, direct association for CD98 in nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) have been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.11.011DOI Listing
January 2020

Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV.

Ann Hepatol 2020 Mar - Apr;19(2):222-225. Epub 2019 Dec 5.

Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Italy; IRCCS-Ospedale Policlinico San Martino, Genoa, Italy. Electronic address:

Chronic hepatitis C virus (HCV) infection and autoimmune disorders show a complex interplay, with HCV often being identified as the trigger of autoimmune phenomena or diseases. While there is evidence of successful HCV treatment with direct-acting antivirals (DAA) in patients with concomitant HCV and autoimmune hepatitis (AIH), there are also sparse reports of AIH developing during, or following, DAA treatment. Here we report a case of a patient with suspected concomitant HCV and AIH who underwent liver biopsy but showed no histological hallmarks of autoimmunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.11.006DOI Listing
December 2019

Osteopontin - A potential biomarker of advanced liver disease.

Ann Hepatol 2020 Jul - Aug;19(4):344-352. Epub 2020 Jan 17.

Charles University in Prague, 1st Faculty of Medicine and General University Hospital, 4th Department of Internal Medicine, U Nemocnice 2, Prague, Czech Republic.

Cirrhosis is a primary cause of liver-related mortality and morbidity. The basic process driving chronic liver disease to cirrhosis is accelerated fibrogenesis. Although the pathogenesis of liver cirrhosis is a multifactorial process, the essential step in the evolution of liver fibrosis is the activation of hepatic stellate cells, which are the main source of collagen produced in the extracellular matrix. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2020.01.001DOI Listing
January 2020

The effects of hyperthermia on human hepatocellular carcinoma stem and mature cancer cells.

Ann Hepatol 2020 May - Jun;19(3):265-268. Epub 2020 Jan 17.

Section of Hepatology, Department of Medicine, Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Pharmacology and Therapeutics, Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address:

Introduction And Objectives: Hepatocellular carcinoma (HCC) can recur following radiofrequency ablation and other hyperthermic treatment modalities. Cancer stem cells (CSCs) are a subpopulation of HCC cells that are difficult to eradicate and largely responsible for tumor recurrences. Thus, the principal objective of this study was to determine whether human HCC CSCs are relatively thermal-resistant compared to non-stem or mature cancer cells (MCCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.12.006DOI Listing
January 2020

Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.

Ann Hepatol 2020 May - Jun;19(3):320-328. Epub 2019 Dec 16.

Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China; The Yunnan Provincial Clinical Center for Hepato-biliary-pancreatic Diseases, Kunming, Yunnan, China. Electronic address:

Introduction: This study aimed to compare the therapeutic efficacy of metformin and other anti-hyperglycemic agents in hepatocellular carcinoma (HCC) patients with type 2 diabetes (T2D).

Materials: A systematic electronic search on keywords including HCC and different anti-hyperglycemic agents was performed through electronic databases including Medline and EMBASE. The primary outcome was the overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.11.008DOI Listing
December 2019

Requirement of cyclin-dependent kinase function for hepatitis B virus cccDNA synthesis as measured by digital PCR.

Ann Hepatol 2020 May - Jun;19(3):280-286. Epub 2019 Dec 28.

Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Basic Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Pathology, National Cheng Kung University Hospital, Tainan, Taiwan. Electronic address:

Introduction And Objectives: HBV covalently closed circular (ccc) DNA is the key player in viral persistence and an important predictive biomarker for hepatitis relapse. Precise quantification of intracellular cccDNA is challenging because cccDNA is present in very low levels in hepatocytes, where it also co-exists with a large excess amount of relaxed circular (rc) DNA. We aimed to develop a highly sensitive cccDNA detection method for cccDNA quantification by digital PCR (dPCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.12.005DOI Listing
December 2019

NRF-2 and nonalcoholic fatty liver disease.

Ann Hepatol 2020 Jan 2. Epub 2020 Jan 2.

Internal Pre-degree Medical of Central Military Hospital, Mexico City, Mexico.

Currently, chronic liver diseases have conditioned morbidity and mortality, many of these with a metabolic, toxicologic, immunologic, viral, or other etiology. Thus, a transcription factor that has been of huge importance for biomedical research is NRF-2. The latter is considered a principal component of the antioxidant mechanism, and it has been acknowledged that it impairs the function of NRF-2 in many liver diseases and that it forms an essential part of the pathologic changes that occur in the liver to contain inflammation and damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.11.010DOI Listing
January 2020

Ruptured hepatocellular carcinoma and non-alcoholic fatty liver disease, a potentially life-threatening complication in a population at increased risk.

Ann Hepatol 2020 Jan - Feb;19(1):3-4

Department of Gastrointestinal Endoscopy, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social. Guadalajara, Jalisco, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.11.001DOI Listing
November 2019

Advancements in genomic medicine and the need for updated regional clinical practice guidelines in the field of hepatology.

Ann Hepatol 2020 Jan - Feb;19(1):1-2

Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, "Fray Antonio Alcalde" and Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.12.002DOI Listing
December 2019

Ocular manifestations of liver disease in children: Clinical aspects and implications.

Ann Hepatol 2019 Dec 20. Epub 2019 Dec 20.

Department of Pediatrics, King George's Medical University, Lucknow 226003, Uttar Pradesh, India. Electronic address:

Liver and eyes are interlinked to each other in various medical conditions. There are certain ocular findings which directly indicate specific liver disorders. Thus, it becomes critical to identify disorders of liver and eyes early in the course of illness, so that prompt management may be initiated before the commencement of complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.11.009DOI Listing
December 2019
2.193 Impact Factor